Histologic changes in fibrocystic breast disease before and after treatment with bromocriptine.
Twenty-five women with fibrocystic breast disease were investigated in a double-blind study using treatment with bromocriptine (5 to 7.5 mg/day for 3 months) or placebo. Estradiol and progesterone measurements did not show any changes before, during or after treatment. Serum prolactin levels were reduced during the use of bromocriptine. Histologic evaluation demonstrated a decrease of epithelial hyperplasia and arrest of the cystic dilation picture after treatment with bromocriptine.
Murta
E F
EF
Department of Gynecology and Obstetrics, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brasil.
de Freitas
M M
MM
Velludo
M A
MA
D000328:Adult; D001706:Biopsy; D001940:Breast / Q000187:drug effects / Q000473:pathology; D001971:Bromocriptine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005348:Fibrocystic Breast Disease / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008597:Menstrual Cycle / Q000097:blood / Q000187:drug effects
D001971:Bromocriptine